drugset
drugset / Trial / NCT03819387

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

NCT03819387 ↗

Phase 1 Completed 49 enrolled Nitto BioPharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).

Timeline

Start
2019-03-18
Primary completion
2023-11-02
Completion
2024-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject NBF-006 Unknown — Intravenous

Indications

colorectal cancer malignant exocrine pancreas neoplasm non-small cell lung carcinoma